Literature DB >> 18973917

Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.

Kenichi Kohashi1, Teiyu Izumi, Yoshinao Oda, Hidetaka Yamamoto, Sadafumi Tamiya, Tomoaki Taguchi, Yukihide Iwamoto, Tadashi Hasegawa, Masazumi Tsuneyoshi.   

Abstract

Loss of SMARCB1/INI1 protein expression is considered useful for confirming a histologic diagnosis of malignant rhabdoid tumor. However, loss of SMARCB1/INI1 protein expression has recently been reported in other tumors as well, including a few cases of epithelioid sarcoma. In addition, the histopathologic differences between proximal-type epithelioid sarcoma and malignant rhabdoid tumor have not been conclusively defined. We analyzed SMARCB1/INI1 protein expression in 54 epithelioid sarcoma (proximal-type, 25; distal-type, 29) and examined alterations of the SMARCB1/INI1 gene in the cases lacking protein expression. We found that 19 (76.0%) proximal-type epithelioid sarcoma and 27 (93.1%) distal-type epithelioid sarcoma showed loss of SMARCB1/INI1 protein expression. Analysis of 39 cases with loss of protein expression revealed 4 cases (10.3%) with SMARCB1/INI1 gene alterations at the DNA level (homozygous deletion, 2; 1- or 2-bp deletion, 2) that could have induced the loss of gene products, and all 4 of these were proximal-type epithelioid sarcoma. Epithelioid sarcoma was thus associated with a high frequency of loss of SMARCB1/INI1 protein expression similar to that in malignant rhabdoid tumor. However, the frequency of SMARCB1/INI1 gene alteration at the DNA level in proximal-type epithelioid sarcoma was significantly lower than that in malignant rhabdoid tumor. In addition, the prognosis of patients with malignant rhabdoid tumor is significantly worse than that of patients with proximal-type epithelioid sarcoma (P = .001). Therefore, proximal-type epithelioid sarcoma and malignant rhabdoid tumor are suggested to be distinctive tumors with respect to the mechanism of the loss of SMARCB1/INI1 protein expression. Analysis of alterations in the SMARCB1/INI1 gene may thus be a useful diagnostic tool to distinguish proximal-type epithelioid sarcoma from malignant rhabdoid tumor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973917     DOI: 10.1016/j.humpath.2008.08.007

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  19 in total

Review 1.  [Epithelioid sarcoma: morphologic variants and differential diagnosis].

Authors:  T Mentzel
Journal:  Pathologe       Date:  2010-03       Impact factor: 1.011

2.  Role of epigenetic modulation for the treatment of sarcoma.

Authors:  Gregory M Cote; Edwin Choy
Journal:  Curr Treat Options Oncol       Date:  2013-09

3.  Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.

Authors:  Elizabeth S McKenna; Pablo Tamayo; Yoon-Jae Cho; Erik J Tillman; E Lorena Mora-Blanco; Courtney G Sansam; Edward C Koellhoffer; Scott L Pomeroy; Charles W M Roberts
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

4.  Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material.

Authors:  Francois Le Loarer; Lei Zhang; Christopher D Fletcher; Agnes Ribeiro; Samuel Singer; Antoine Italiano; Agnes Neuville; Aurélie Houlier; Frederic Chibon; Jean-Michel Coindre; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2014-03-03       Impact factor: 5.006

5.  Proximal-type epithelioid sarcoma in the groin presenting as a diagnostic dilemma.

Authors:  Abul Ala Syed Rifat Mannan; Amre A Rifaat; Mirza Kahvic; Kusum Kapila; Mrinmay Mallik; Vinod Kumar Grover; Chandramouli Bharati; Arie Perry
Journal:  Pathol Oncol Res       Date:  2009-09-08       Impact factor: 3.201

6.  Reclassification of rhabdoid tumor and pediatric undifferentiated/unclassified sarcoma with complete loss of SMARCB1/INI1 protein expression: three subtypes of rhabdoid tumor according to their histological features.

Authors:  Kenichi Kohashi; Yukichi Tanaka; Hiroshi Kishimoto; Hidetaka Yamamoto; Yuichi Yamada; Tomoaki Taguchi; Yukihide Iwamoto; Yoshinao Oda
Journal:  Mod Pathol       Date:  2016-06-22       Impact factor: 7.842

Review 7.  Soft Tissue Special Issue: Skeletal Muscle Tumors: A Clinicopathological Review.

Authors:  Kenichi Kohashi; Izumi Kinoshita; Yoshinao Oda
Journal:  Head Neck Pathol       Date:  2020-01-16

8.  Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 in childhood chordomas.

Authors:  Rajni Yadav; Mehar Chand Sharma; Prit Benny Malgulwar; Pankaj Pathak; Elanthenral Sigamani; Vaishali Suri; Chitra Sarkar; Amandeep Kumar; Manmohan Singh; Bhawani Shankar Sharma; Ajay Garg; Sameer Bakhshi; Mohammed Faruq
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

9.  Proximal-type Epithelioid Sarcoma of the Head and Neck (HN): A Study with Immunohistochemical and Molecular Analysis of SMARCB1.

Authors:  Renee Frank; Navid Sadri; Tricia Bhatti; Jaclyn A Biegel; Virginia A Livolsi; Paul J Zhang
Journal:  J Clin Exp Oncol       Date:  2013

Review 10.  Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.

Authors:  Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller
Journal:  Front Oncol       Date:  2015-08-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.